HK Stock Market Move | WUXI BIO (02269) opened over 3% higher in the morning, with an expected net profit of 4.908 billion yuan in 2025, a year-on-year growth of 46.3%.

WUXI BIO (02269) opened more than 3% higher after the market, rising 3.55% to HK$41.44 as of the time of writing, with a turnover of HK$2184.22 million. On the news front, WUXI BIO announced that it expects the group's revenue for the fiscal year 2025 to increase by approximately 16.7% to RMB 21.79 billion; gross profit margin to increase by about 5 percentage points to 46% year-on-year; adjusted gross profit to increase by about 25.5% to approximately RMB 10.638 billion. Profit and profit attributable to equity shareholders of the company are expected to increase by approximately 45.3% to RMB 5.733 billion and approximately 46.3% to RMB 4.908 billion; adjusted net profit is expected to increase by about 22% to RMB 6.586 billion year-on-year. The announcement stated that the revenue growth of WUXI BIO is attributed to the successful execution of the "Follow and Win Molecules" strategy, as well as the leading technology platform, industry-best project delivery times, and outstanding track record of project execution. Other factors include: revenue growth from research services generated by multiple advanced technologies of the group; utilization of existing and new capacities, including the ramp-up of capacity at the European production base; cost savings and efficiency improvements achieved through lean operational management systems and digital solutions, as well as investment returns from the investment portfolio.